Fact and fiction in tuberculosis vaccine research: 10 years later.
DOI: 10.1016/S1473-3099(11)70146-3
关键词:
摘要: Summary Tuberculosis is one of the most deadly infectious diseases. The situation worsening because co-infection with HIV and increased occurrence drug resistance. Although BCG vaccine has been in use for 90 years, protection insufficient; new candidates are therefore needed. 12 potential vaccines have gone into clinical trials. Ten aimed at prevention tuberculosis and, these, seven subunit either as adjuvanted or viral-vectored antigens. These would be boosters BCG-prime vaccination. Three recombinant constructs—possible replacements BCG. Additional will enter trials near future, including postexposure individuals latent infection. In long term, that prevent eradicate infection Mycobacterium best possible option. Improved knowledge immunology, molecular microbiology, cell biology, biomics, biotechnology paved way towards an effective safe against tuberculosis. pipeline from preclinical to testing could accelerated by development biomarkers can predict outcome
mpg.de
elsevier.com
sci-hub.se 参考文章(86)
Hanekom WA Hatherill M, Adams V, Hughes J, De Kock M, Mavakla W, Pienaar B, Mahomed H, Hussey G, None, The potential impact of helminth infection on trials of novel tuberculosis vaccines Vaccine. ,vol. 27, pp. 4743- 4744 ,(2009) , 10.1016/J.VACCINE.2009.05.021
Paul E. M. Fine, The BCG Story: Lessons from the Past and Implications for the Future Clinical Infectious Diseases. ,vol. 11, ,(1989) , 10.1093/CLINIDS/11.SUPPLEMENT_2.S353
L. J. Abu-Raddad, L. Sabatelli, J. T. Achterberg, J. D. Sugimoto, I. M. Longini, C. Dye, M. E. Halloran, Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 13980- 13985 ,(2009) , 10.1073/PNAS.0901720106
Claus Aagaard, Truc Hoang, Jes Dietrich, Pere-Joan Cardona, Angelo Izzo, Gregory Dolganov, Gary K Schoolnik, Joseph P Cassidy, Rolf Billeskov, Peter Andersen, A multistage tuberculosis vaccine that confers efficient protection before and after exposure Nature Medicine. ,vol. 17, pp. 189- 194 ,(2011) , 10.1038/NM.2285
C. Sander, H. McShane, Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis. Clinical and Experimental Immunology. ,vol. 147, pp. 401- 411 ,(2007) , 10.1111/J.1365-2249.2006.03306.X
Stefan H.E. Kaufmann, Future Vaccination Strategies Against Tuberculosis: Thinking Outside the Box Immunity. ,vol. 33, pp. 567- 577 ,(2010) , 10.1016/J.IMMUNI.2010.09.015
Kenneth Von Eschen, Royce Morrison, Madeleine Braun, Opokua Ofori-Anyinam, Els De Kock, Priya Pavithran, Marguerite Koutsoukos, Philippe Moris, Daniel Cain, Marie-Claude Dubois, Joe Cohen, W. Ripley Ballou, The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Human Vaccines. ,vol. 5, pp. 475- 482 ,(2009) , 10.4161/HV.8570
Karen Lingnau, Karin Riedl, Alexander von Gabain, IC31® and IC30, novel types of vaccine adjuvant based on peptide delivery systems Expert Review of Vaccines. ,vol. 6, pp. 741- 746 ,(2007) , 10.1586/14760584.6.5.741
K.B. Walker, M.J. Brennan, M.M. Ho, J. Eskola, G. Thiry, J. Sadoff, R. Dobbelaer, L. Grode, M.A. Liu, U. Fruth, P.H. Lambert, The second Geneva Consensus: Recommendations for novel live TB vaccines Vaccine. ,vol. 28, pp. 2259- 2270 ,(2010) , 10.1016/J.VACCINE.2009.12.083
Graham A. Colditz, Efficacy of BCG Vaccine in the Prevention of Tuberculosis JAMA. ,vol. 271, pp. 698- 702 ,(1994) , 10.1001/JAMA.1994.03510330076038